The 6 biggest crossover rounds in biopharma history

A strong crossover raise can suggest that a company has “reached a level of maturity” and could go public soon, according to Sofinnova Investments’ Jim Healy.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top